

The phosphatase, pp2a as a classifier to stratify patients into therapeutic groups

Dr Godfrey Grech Pathology Department University of Malta

Thursday 9th - Friday 10th February 2012 Aula Magna Sapienza University of Roma



Cellular models utilised to study mechanism of disease

Identification of potential therapeutic targets

Genomics used to stratify patients into subtypes

Biomarkers used as classifiers of specific therapeutic groups

Mechanism of Disease

Therapeutic targets

Biomarkers







Mechanism of Disease

Therapeutic targets

Biomarkers

Blazquez-Domingo, M.*, **Grech, G**.* and von Lindern, M. (**2005**) Translation Initiation Factor 4E Inhibits Differentiation of Erythroid Progenitors.

Mol. Cell. Biol., 25, 8496-8506.





Biomarkers

Gene expression profiling polysome bound vs Total mRNA





Mechanism of Disease

Erasmus MC University Medical Center Rotterdam

zamo

Therapeutic targets

Biomarkers





Erasmus MC University Medical Center Rotterdam

zafino

Therapeutic targets

Biomarkers





Therapeutic targets

Biomarkers

Grech, G., et al. (**2008)** Blood Oct 1;112(7):2750-60.





TGF-β rescues block of differentiation

FTY720 activates pp2a resulting in the release of differentiation block by Stem Cell Factor.

Neville Borg, 2009

unpublished data



Mechanism of Disease

Therapeutic targets

Biomarkers

Genomics utilised to study mechanism of disease

Identification of potential therapeutic targets

Genomics used to stratify patients into subtypes

Biomarkers used as classifiers of specific therapeutic groups





Mechanism of Disease

Therapeutic targets

Biomarkers

Valk P.J.M., et al. N Eng J Med 350;16 April 15, 2004



Genomics used to stratify patients into subtypes

Biomarkers used as classifiers of specific therapeutic groups





Mechanism of Disease

Therapeutic targets

Biomarkers

Regulators of pp2a activity





3rd Annual Course Regulators of pp2a activity Pharmacogenetics and Personalised Medicine SETBP1 CIP2A Expression of pp2a inhibitors Mechanism of Disease Therapeutic targets **Biomarkers** Erasmus MC University Medical Center Rotterdam zamo



Mechanism of Disease

Therapeutic targets

Biomarkers

Regulators of pp2a activity

High Resolution Melting (HRM) Analysis

- Screening for coding sequence variations
- Characterisation of isoforms





Mechanism of Disease

Therapeutic targets

Biomarkers

Conclusions

- High expression of SETBP1 in a subtype of de novo AML
- Mutations were identified in myeloid cell lines in the pp2a regulators, Igbp1 and SET
- Genomics approach to classify and identify therapeutic groups sensitive to pp2a activators





Thank you





Dr Christian Saliba

PostDoc



Bridget Ellul Head of Department

James DeGaetano Sharon Falzon *Mater Dei Hospital*

Neville Borg Nigel Borg Mareh Dalal *MSc students*

Shawn Baldacchino *PhD student*